Hoffmann-La Roche Inc.

F. Hoffmann-La Roche Ag

Morphosys Ag

Bernd Bohrmann

Walter Huber

Manfred Brockhaus

Hansruedi Loetscher

Olaf Mundigl

Ulrich Goepfert

Fiona Grueninger

Michael Schraeml

Christine Rothe

Michael Otto Bardroff

Corinna Löhning

Titus Kretzschmar

Christer Nordstedt

Guy Georges

Kurt Lang

Hubert Kettenberger

Hans-Willi Krell

Joerg Benz

Andreas Schaubmar

Valeria Lifke

Sonja Offner

Hans Koll

Karl Weyer

Laurence Ozmen

Diana Schuhbauer

Michael Schraemi

Antonio Iglesias

Peter Maier

Jens Niewoehner

Alain Tissot-Daguette

Per-Ola Freskgard

Eduard Urich

The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.

Humanized anti-Tau(pS422) antibodies and methods of use

An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.

Use of an anti-Tau pS422 antibody for the treatment of brain diseases

The present invention relates to a purified antibody molecule preparation being characterized in that at least one antigen binding site comprises a glycosylated asparagine (Asn) in the variable region of the heavy chain (V). More specifically, a pharmaceutical and a diagnostic composition comprising said antibody molecule and antibody mixtures are provided which is/are capable of specifically recognizing the &#x3b2;-A4 peptide/A&#x3b2;4. The present invention relates in particular to a mixture of antibodies comprising one or two glycosylated antigen binding sites with a glycosylated asparagine (Asn) in the variable region of the heavy chain, i.e. mixtures of isoforms of antibodies which comprise a glycosylated Asn in the variable region of the heavy chain (V). Also disclosed are compositions or antibody preparations comprising the specifically glycosylated antibody isoforms. Furthermore, the pharmaceutical and diagnostic uses for these antibodies are provided. The antibody isoforms may for example be used in the pharmaceutical intervention of amyloidogenesis or amyloid-plaque formation and/or in the diagnosis of the same.

Antibodies against amyloid beta 4 with glycosylation in the variable region

The present invention relates to antibody molecules capable of specifically recognizing two regions of the &#x3b2;-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.

Nucleic acid molecules encoding anti-amyloid beta antibodies

Anti-A&#x3b2; antibodies and their use

The present invention relates to antibody molecules capable of specifically recognizing two regions of the R-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.

Anti-amyloid &#x3b2; antibodies

Growing community of inventors

Riehen, Switzerland

Bernd Bohrmann